AML

Which statement is CORRECT about lineage-specific antigen expression in the WHO classification?

(A) MPO (myeloperoxidase) is myeloid specific antigen

(B) Monocytic differentiation (at least two of nonspecific esterase, CD11c, CD14, CD64, lysozyme) is myeloid specific antigen

(C) Cytoplasmic CD3 (flow cytometry with antibodies to CD3 epsilon chain) is T-lymphoid specific

(D) Strong CD19 with at least 1 of the following strongly expressed: CD79a, cytoplasmic CD22, or CD10 is B-lymphoid specific

(E) All of the above.

According to 2017 European LeukemiaNet (ELN) risk stratification in acute myeloid leukemia (AML), which statement is WRONG？

(A) AML patient with biallelic mutated CEBPA is classified as favorable risk group.

(B) AML patient with mutated NPM1 but without FLT3-ITD is classified as favorable risk group.

(C) AML patient with wild type NPM1 and low allelic ratio FLT3-ITD is classified as intermediate risk group.

(D) AML patient with normal cytogenetics and RUNX1 mutation is classified as adverse risk group.

(E) AML patient with wild-type NPM1 and high allelic ratio FLT3-ITD is classified as intermediate unfavorable risk group.

Based on the 2017 ELN recommendation, which one of the following genetic/cytogenetic change is NOT categorized as an adverse risk for patients with AML?

(A) Monosomal karyotype

(B) t(9;11)(p21.3;q23.3)

(C) t(3;3)(q21.3;q26.2)

(D) Mutated RUNX1 in the absence of other genetic/cytogenetic change